Concepedia

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism

Huiyan Shi, Jin Yan, Wenhui Zhu, Guoping Yang, Zhi‐Rong Tan, Weihua Wu, Gan Zhou, Xiaoping Chen, Dongsheng Ouyang

European Journal of Clinical Pharmacology · 2010 · 50 citations · 22 references

DOIFull text

Open access

Abstract

Both CYP2C19 genotypes and CYP3A4 inhibitor erythromycin can influence the plasma concentration of voriconazole, and erythromycin increases plasma concentration of voriconazole in a CYP2C19 genotype-dependent manner.

References

22

Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis

Raoul Herbrecht, David W. Denning, Thomas F. Patterson et al. · New England Journal of Medicine · 2002 · 3.3K citations · Full text

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

S.M. de Morais, G. Wilkinson, Joyce Blaisdell et al. · Journal of Biological Chemistry · 1994 · 952 citations · Full text

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

John R. Perfect, Kieren A. Marr, Thomas J. Walsh et al. · Clinical Infectious Diseases · 2003 · 674 citations · Full text

, , +13

Pharmacokinetic/Pharmacodynamic Profile of Voriconazole

Ursula Theuretzbacher, Franziska Ihle, Hartmut Derendorf · Clinical Pharmacokinetics · 2006 · 464 citations

, , +4

Identification of the Cytochrome P450 Enzymes Involved in the N-Oxidation of Voriconazole

Ruth Hyland, B. C. Jones, Dennis A. Smith · Drug Metabolism and Disposition · 2003 · 376 citations